Biocon Biologics received US Food and Drug Administration (USFDA) approval for biosimilar Yesafili, a vascular endothelial growth factor inhibitor for various ophthalmology conditions, including age-related macular degeneration. Yesafili is similar to Eylea. CEO Shreehas Tambe highlighted the company's milestone in bringing interchangeable insulin and biosimilars to patients. The approval comes as 19.8 million Americans live with macular degeneration, with aflibercept sales reaching $5.89 billion in 2023.
